Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical amphotericin gel for cutaneous leishmaniasis
IRCT20221205056717N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2022
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial in cutaneous leishmaniasis (CL) comparing Amphotericin gel plus standard treatment with Placebo ointment plus standard treatment (2 arms). Primary endpoints: Change in lesion size and Change in lesion induration. Started Dec 2022; status: completed.
02
Drugs
liposomal amphotericin b
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20221205056717N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221205056717N1.